Pharma/Fine Chemicals Roundup – May 1

WATSON PHARMACEUTICALS TO ACQUIRE ACTAVIS FOR $5.6 BILLION Watson Pharmaceuticals (Parsippany, NJ), a leading manufacturer of generic, branded and biologic pharmaceutical products, and privately held generic pharmaceuticals company Actavis (Zug, Switzerland) say that Watson has entered into a definitive agreement to acquire Actavis for €4.25 billion ($5.6 billion). The announcement of the acquisition confirms an earlier report. Watson expects the transaction to close in the fourth quarter of 2012. Following the acquisition, Watson will become the third...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers